Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $370.2 million.

  • Xeris Biopharma Holdings' Liabilities and Shareholders Equity rose 1528.69% to $370.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 238.82%. This contributed to the annual value of $323.1 million for FY2024, which is 14.2% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Liabilities and Shareholders Equity stood at $370.2 million for Q3 2025, which was up 1528.69% from $334.7 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Liabilities and Shareholders Equity peaked at $370.2 million during Q3 2025, and registered a low of $131.3 million during Q3 2021.
  • In the last 5 years, Xeris Biopharma Holdings' Liabilities and Shareholders Equity had a median value of $323.1 million in 2024 and averaged $316.0 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Liabilities and Shareholders Equity soared by 13085.25% in 2022 and then plummeted by 636.24% in 2023.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Liabilities and Shareholders Equity stood at $304.4 million in 2021, then grew by 13.2% to $344.5 million in 2022, then decreased by 6.36% to $322.6 million in 2023, then rose by 0.14% to $323.1 million in 2024, then increased by 14.59% to $370.2 million in 2025.
  • Its last three reported values are $370.2 million in Q3 2025, $334.7 million for Q2 2025, and $315.5 million during Q1 2025.